Read transcripts of debates in both Houses
Produced by Commons Library, Lords Library and Parliamentary Office Science and Technology
Search for Members by name, postcode, constituency and party
Learn about their experience, knowledge and interests
Celebrating people who have made Parliament a positive, inclusive working environment
Four staff networks for people to discuss and consider issues.
2018 marks 100 years since some women, and all men, could vote. Find out how you can join in
Sign up for the Your Parliament newsletter to find out how you can get involved
Take a tour of Parliament and enjoy a delicious afternoon tea by the River Thames
See some of the sights you’ll encounter on a tour of Parliament
Book a school visit, classroom workshop or teacher-training session
Access videos, worksheets, lesson plans and games
Follow this EDM by:
That this House notes with concern that the National Institute for Health and Care Excellence (NICE) has issued a draft recommendation which will limit the use of the drug enzalutamide, a life extending treatment for men in the final stages of prostate cancer, only to those men who have not received another drug called abiraterone; further notes with concern that this decision will result in men having no other options on the NHS; is aware that prostate cancer is the most common cancer in men in the UK, that 36,566 men are diagnosed with prostate cancer and that 10,000 men die from the disease in England and Wales every year; further notes that there is no way for clinicians to tell which treatment - enzalutamide or abiraterone - will work best for men, making it important for both treatment options to be available to men without this restriction; calls on the Government to ensure that men with prostate cancer are able to access both cancer drugs to treat their health condition and to help prolong their life; and further calls on NICE to reconsider its draft decision and recommend enzalutamide as an alternative treatment to abiraterone, if their clinicians prescribe it.
Total number of signatures: 22
Showing 22 out of 22